Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation
of Collateral Pathways

Sikirić, Predrag; Gojkovic, Slaven; Knežević, Martina; Tepes, Marijan; Strbe, Sanja; Vukojević, Jakša; Duzel, Antonija; Kralj, Tamara; Krezic, Ivan; Zizek, Helena; Oroz, Katarina; Vranes, Hrvoje; Smoday, Ivan Maria; Kalogjera, Luka; Vlainić, Josipa; Kokot, Antonio; Jurjević, Ivana; Blagaić, Alenka Boban; Škrtić, Anita; Seiwerth, Sven

doi:10.2174/0929867329666221005111553

Cited by 14 publications

(150 citation statements)

References 31 publications

Supporting

Mentioning

125

Contrasting

Order By: Relevance

“…As previously shown (for review, see [ 1 , 2 , 3 , 4 , 5 , 6 ]), all of the studies to date that have tested the stable gastric pentadecapeptide BPC 157 peptide—native to and stable in human gastric juice, even for periods of time longer than 24 h—as a treatment have demonstrated extremely positive healing effects for various injury types in numerous organ systems, particularly for the muscular system. These might be injuries directly to the muscle or various muscle disabilities deriving from a multitude of causes, peripheral and/or central (for review, see [ 1 , 7 , 8 , 9 ]).…”

Section: Introductionmentioning

confidence: 99%

“…This paper attempts to review, in a particular way, the stable gastric pentadecapeptide BPC 157 (for review see, i.e., [ 1 , 2 , 3 , 4 , 5 , 6 ]) and its effects on striated, smooth, and heart muscles.…”

Section: Introductionmentioning

confidence: 99%

“…These might be injuries directly to the muscle or various muscle disabilities deriving from a multitude of causes, peripheral and/or central (for review, see [ 1 , 7 , 8 , 9 ]). As an additional effect, there is also the maintenance and recovery of smooth muscle function, and BPC 157 therapy might promote recovery of sphincter functions (for review, see [ 1 , 2 , 3 , 4 , 5 , 6 ]). As an illustration, it has been shown to counteract tumor-induced muscle cachexia and the signaling process implicated in cancer cachexia [ 10 ] and leaky gut [ 11 ], as well as its membrane stabilizing and free radical scavenging activities (for review see, [ 10 , 11 ]).…”

Section: Introductionmentioning

confidence: 99%

“…As an illustration, it has been shown to counteract tumor-induced muscle cachexia and the signaling process implicated in cancer cachexia [ 10 ] and leaky gut [ 11 ], as well as its membrane stabilizing and free radical scavenging activities (for review see, [ 10 , 11 ]). Furthermore, its effects on damaged skin, muscle, tendon, and bone are comparable to those in the gastrointestinal tract (and liver, pancreas lesions) [ 1 ], kidney and cardiovascular system (particularly affecting blood vessels and vessel recruitment as part of therapy for heart failure and lung lesions, counteracting arrhythmias and thrombosis) [ 5 , 6 ]. Conceptually, its practical significance has been ascribed to its particular role in the Selye’s stress response [ 3 , 7 , 8 ], as well as to its resolving of activities of the brain–gut and gut–brain axes [ 7 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, with BPC 157 therapy, the epithelium/endothelium protection is an innate cytoprotective capability of the agent, and represents, thereby, the essential principle of the cytoprotection principle. Endothelium protection→epithelium protection has been promoted as the particular upgrade of a minor vessel in taking over the function of a disabled major vessel (for review, see [ 5 , 6 , 33 ]). With severe syndromes, such as vascular and multiorgan failure following major vessel occlusion or similar noxious procedures [ 66 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 ], the particular activation of the collateral pathways (i.e., azygos vein direct blood delivery) might be essential to counteract severe central and peripheral lesions, intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

et al. 2022

Self Cite

View full text Add to dashboard Cite

First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and bone injuries, applied alone, as native peptide therapy, effective in rat injury, given intraperitoneally or in drinking water or topically, at the site of injury. As a follow up, we reviewed that with the BPC 157 therapy, its cytoprotective ability to organize simultaneous healing of different tissues of and full recovery of the myotendinous junction might represent the particular muscle therapy against distinctive etiopathology muscle disabilities and weakness. In this, BPC 157 therapy might recover many of muscle disabilities (i.e., succinylcholine, vascular occlusion, spinal cord compression, stroke, traumatic brain injury, severe electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome and NO-system blockade and tumor-cachexia). These might provide practical realization of the multimodal muscle-axis impact able to react depending on the condition and the given agent(s) and the symptoms distinctively related to the prime injurious cause symptoms in the wide healing concept, the concept of cytoprotection, in particular. Further, the BPC 157 therapy might be the recovery for the disabled heart functioning, and disabled smooth muscle functioning (various sphincters function recovery). Finally, BPC 157, native and stable in human gastric juice, might be a prototype of anti-ulcer cytoprotective peptide for the muscle therapy with high curing potential (very safe profile (lethal dose not achieved), with suited wide effective range (µg-ng regimens) and ways of application).

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection

Sikiric,

Sever,

Krezic

et al. 2024

Inflammopharmacol

View full text Add to dashboard Cite

Cysteamine HCl Administration Impedes Motor and Olfactory Functions Accompanied by Reduced Dopaminergic Neurons in Experimental Mice: A Preclinical Mimetics Relevance to Parkinson’s Disease

Selvaraj,

Panneerselvam,

Vergil Andrews

et al. 2024

Preprint

View full text Add to dashboard Cite

Cysteamine HCl has been established as a potent ulcerogenic agent of the gastrointestinal (GI) system. GI dysfunction and olfactory deficits are the most common clinical symptoms of many movement disorders including Parkinson's disease (PD). Cysteamine HCl has been shown to interfere with dopamine, a neurotransmitter crucial for motor, olfactory, and cognitive functions. However, the reports on the effect of cysteamine HCl treatment on the behavior and dopamine system appear to be inconsistent. Therefore, we revisited the impact of cysteamine HCl on motor function in experimental mice using a battery of behavioral tests such as pole test (PT), beam walking test (BWT), and rotarod test (RDT), while the olfactory ability and cognitive functions were examined through food buried test (FBT) and Y maze. Furthermore, we investigated the effect of cysteamine HCl on the density of dopaminergic tyrosine hydroxylase (TH)-positive cells in the substantia nigra (SN) and olfactory bulb (OB) of experimental mice using immunohistochemistry. Results revealed that cysteamine HCl administration in mice induced significant impairments in motor balance and coordination, as their movement-related performance was markedly reduced in behavioral tasks. Mice exposed to cysteamine HCl showed a pronounced reduction in odor discrimination ability and cognitive impairments. Strikingly, the number of TH-positive neurons was found to be reduced in the SN and OB of the cysteamine HCl-treated group which is a bonafide neuropathogenic hallmark of PD. This study highlights the potential neurotoxic effects of cysteamine HCl in experimental brains and suggests further investigation into its role in pathogenesis of Parkinsonism.

show abstract

Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways

Cited by 14 publications

References 31 publications

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle

New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection

Cysteamine HCl Administration Impedes Motor and Olfactory Functions Accompanied by Reduced Dopaminergic Neurons in Experimental Mice: A Preclinical Mimetics Relevance to Parkinson’s Disease

Contact Info

Product

Resources

About